Geode Capital Management LLC Buys 95,900 Shares of VolitionRx Limited (NYSE:VNRX)

Geode Capital Management LLC grew its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period.

Separately, Ground Swell Capital LLC grew its stake in VolitionRx by 78.8% during the third quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock valued at $28,000 after acquiring an additional 20,249 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Price Performance

Shares of VolitionRx stock opened at $0.65 on Monday. VolitionRx Limited has a 1 year low of $0.43 and a 1 year high of $1.23. The firm has a market cap of $60.42 million, a PE ratio of -1.81 and a beta of 1.20. The company has a 50 day simple moving average of $0.65 and a two-hundred day simple moving average of $0.66.

Insider Activity

In other news, Director Guy Archibald Innes acquired 174,764 shares of VolitionRx stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Cameron John Reynolds acquired 139,811 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 358,266 shares of company stock worth $204,212. 12.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a report on Wednesday, January 8th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. Finally, StockNews.com assumed coverage on VolitionRx in a research report on Tuesday, January 7th. They set a “sell” rating for the company.

VolitionRx Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.